Business Wire

NY-GAIN-THEORY

16.1.2020 14:02:12 CET | Business Wire | Press release

Share
Gain Theory Recognized as a Strong Performer in Marketing Measurement and Optimization

Gain Theory , a WPP global marketing effectiveness consultancy that empowers marketers to create agile, smarter, data-informed cultures via data, technology and advanced analytics has been named a Strong Performer in The Forrester Wave™: Marketing Measurement and Optimization Solutions, Q1 2020. Gain Theory received the highest score possible for ten criteria including: Unified Measurement Methodology; Training and Change Management Services; Marketing Strategy Consulting; Engagement Structures; Marketing Dashboards and Reports; and Global Strategy.

The report recognizes Gain Theory’s work measuring marketing’s impact on both short and long-term business objectives and helping clients develop plans to optimize multiple objectives simultaneously. The report states: "Firms looking for more complex insights and drivers of marketing performance should put Gain Theory on their short list." Forrester notes Gain Theory’s "investments in data partnerships and machine learning to increase speed of insight." Forrester also notes Gain Theory’s deep focus on change management to help clients with the skillset development and organizational restructuring often required to activate marketing insights.

Forrester gives Gain Theory high marks for its Unified Measurement approach which "leverages a system of models that iterate and inform each other." Gain Theory’s approach is unified at three levels: data, analytics and outcomes and crafted to individual client needs. Clients note that the "sophistication" of Gain Theory’s unified model is its "main strength." Also cited is Gain Theory Sensor™ which combines individual and aggregate data to measure the value of individual campaign tactics and to conduct in-campaign tests. Sensor is a component of Gain Theory’s Unified Measurement approach but can also be used as a stand-alone solution.

"We are delighted to be recognized as a Strong Performer in Forrester’s Wave report," said Gain Theory Global CEO, Manjiry Tamhane. "It confirms for us the unique value that we deliver to our clients globally who trust us to make a meaningful difference to their business performance through our focus on improving marketing efficiency, growing market share and seeing baseline profits and share price grow. At Gain Theory we are passionate about inspiring marketing excellence and creating data-informed cultures. Championing our clients and solving their challenges is what makes our people thrive and we believe the Forrester Wave result is a testament to this."

About Gain Theory

Gain Theory is a global marketing effectiveness consultancy, empowering marketing and insight professionals to create agile, smarter , data-informed cultures using data, technology and advanced analytics .

As an independent practice within WPP , Gain Theory is trusted by clients around the world to enhance business performance in both the short and long-term by improving marketing effectiveness and efficiency, increasing baseline profits, growing market share and driving share price growth .

The global team consists of 200+ consultants, data scientists, mathematicians and marketing technology specialists who operate globally servicing 113 markets worldwide.

gaintheory.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye